-DOCSTART- -X- O
The -X- _ O
pathogenesis -X- _ O
of -X- _ O
autoimmune -X- _ O
diseases -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
rheumatoid -X- _ B-Patient
arthritis -X- _ I-Patient
( -X- _ I-Patient
RA -X- _ I-Patient
) -X- _ I-Patient
and -X- _ I-Patient
systemic -X- _ I-Patient
lupus -X- _ I-Patient
erythematosus -X- _ I-Patient
( -X- _ I-Patient
SLE -X- _ I-Patient
) -X- _ I-Patient
is -X- _ O
driven -X- _ O
by -X- _ O
genetic -X- _ O
predisposition -X- _ O
and -X- _ O
environmental -X- _ O
triggers -X- _ O
that -X- _ O
lead -X- _ O
to -X- _ O
dysregulated -X- _ O
immune -X- _ O
responses. -X- _ O
These -X- _ O
include -X- _ O
the -X- _ O
generation -X- _ O
of -X- _ O
pathogenic -X- _ O
autoantibodies -X- _ O
and -X- _ O
aberrant -X- _ O
production -X- _ O
of -X- _ O
inflammatory -X- _ O
cytokines. -X- _ O
Current -X- _ O
therapies -X- _ O
for -X- _ O
RA -X- _ O
and -X- _ O
other -X- _ O
autoimmune -X- _ O
diseases -X- _ O
reduce -X- _ O
inflammation -X- _ O
by -X- _ O
targeting -X- _ O
inflammatory -X- _ O
mediators -X- _ O
, -X- _ O
most -X- _ O
of -X- _ O
which -X- _ O
are -X- _ O
innate -X- _ O
response -X- _ O
cytokines -X- _ O
, -X- _ O
resulting -X- _ O
in -X- _ O
generalized -X- _ O
immunosuppression. -X- _ B-Comparison
Overall -X- _ O
, -X- _ O
this -X- _ O
strategy -X- _ O
has -X- _ O
been -X- _ O
very -X- _ O
successful -X- _ O
, -X- _ O
but -X- _ O
not -X- _ O
all -X- _ O
patients -X- _ O
respond -X- _ O
, -X- _ O
responses -X- _ O
can -X- _ O
diminish -X- _ O
over -X- _ O
time -X- _ O
and -X- _ O
numerous -X- _ O
side -X- _ O
effects -X- _ O
can -X- _ O
occur. -X- _ O
Therapies -X- _ O
that -X- _ O
target -X- _ O
the -X- _ O
germinal -X- _ O
center -X- _ O
( -X- _ O
GC -X- _ O
) -X- _ O
reaction -X- _ O
and -X- _ O
/ -X- _ O
or -X- _ O
antibody-secreting -X- _ O
plasma -X- _ O
cells -X- _ O
( -X- _ O
PC -X- _ O
) -X- _ O
potentially -X- _ O
provide -X- _ O
a -X- _ O
novel -X- _ O
approach. -X- _ O
TANK-binding -X- _ B-Intervention
kinase -X- _ I-Intervention
1 -X- _ I-Intervention
( -X- _ I-Intervention
TBK1 -X- _ I-Intervention
) -X- _ I-Intervention
is -X- _ O
an -X- _ O
IKK-related -X- _ O
serine -X- _ O
/ -X- _ O
threonine -X- _ O
kinase -X- _ O
best -X- _ O
characterized -X- _ O
for -X- _ O
its -X- _ O
involvement -X- _ O
in -X- _ O
innate -X- _ O
antiviral -X- _ O
responses -X- _ O
through -X- _ O
the -X- _ O
induction -X- _ O
of -X- _ O
type -X- _ O
I -X- _ O
interferons. -X- _ O
TBK1 -X- _ O
is -X- _ O
also -X- _ O
gaining -X- _ O
attention -X- _ O
for -X- _ O
its -X- _ O
roles -X- _ O
in -X- _ O
humoral -X- _ O
immune -X- _ O
responses. -X- _ O
In -X- _ O
this -X- _ O
review -X- _ O
, -X- _ O
we -X- _ O
discuss -X- _ O
the -X- _ O
role -X- _ O
of -X- _ O
TBK1 -X- _ O
in -X- _ O
immunological -X- _ O
pathways -X- _ O
involved -X- _ O
in -X- _ O
the -X- _ O
development -X- _ O
and -X- _ O
maintenance -X- _ O
of -X- _ O
antibody -X- _ O
responses -X- _ O
, -X- _ O
with -X- _ O
particular -X- _ O
emphasis -X- _ O
on -X- _ O
its -X- _ O
potential -X- _ B-Outcome
relevance -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
pathogenesis -X- _ I-Outcome
of -X- _ I-Outcome
humoral -X- _ I-Outcome
autoimmunity. -X- _ I-Outcome
First -X- _ I-Outcome
, -X- _ I-Outcome
we -X- _ I-Outcome
review -X- _ I-Outcome
the -X- _ I-Outcome
role -X- _ I-Outcome
of -X- _ I-Outcome
TBK1 -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
induction -X- _ I-Outcome
of -X- _ I-Outcome
type -X- _ I-Outcome
I -X- _ I-Outcome
IFNs. -X- _ I-Outcome
Second -X- _ I-Outcome
, -X- _ I-Outcome
we -X- _ I-Outcome
highlight -X- _ I-Outcome
how -X- _ I-Outcome
TBK1 -X- _ I-Outcome
mediates -X- _ I-Outcome
inducible -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
co-stimulator -X- _ I-Outcome
signaling -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
GC -X- _ I-Outcome
T -X- _ I-Outcome
follicular -X- _ I-Outcome
B -X- _ I-Outcome
helper -X- _ I-Outcome
population. -X- _ I-Outcome
Third -X- _ I-Outcome
, -X- _ I-Outcome
we -X- _ I-Outcome
discuss -X- _ I-Outcome
emerging -X- _ I-Outcome
evidence -X- _ I-Outcome
on -X- _ I-Outcome
the -X- _ I-Outcome
contribution -X- _ I-Outcome
of -X- _ I-Outcome
TBK1 -X- _ I-Outcome
to -X- _ I-Outcome
autophagic -X- _ I-Outcome
pathways -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
potential -X- _ I-Outcome
implications -X- _ I-Outcome
for -X- _ I-Outcome
immune -X- _ I-Outcome
cell -X- _ I-Outcome
function. -X- _ I-Outcome
Finally -X- _ I-Outcome
, -X- _ I-Outcome
we -X- _ I-Outcome
discuss -X- _ I-Outcome
the -X- _ I-Outcome
therapeutic -X- _ I-Outcome
potential -X- _ I-Outcome
of -X- _ I-Outcome
TBK1 -X- _ I-Outcome
inhibition -X- _ I-Outcome
in -X- _ I-Outcome
autoimmunity -X- _ I-Outcome
. -X- _ O

